JSPR: Jasper Therapeutics, Inc. Stock

by  •  • Comments Off on JSPR: Jasper Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 81.72
Enterprise Value ($M) 10.08
Book Value ($M) 61.67
Book Value / Share 4.11
Price / Book 1.33
NCAV ($M) 57.59
NCAV / Share 3.83
Price / NCAV 1.42

Profitability (mra)
Return on Invested Capital (ROIC) -1.12
Return on Assets (ROA) -0.75
Return on Equity (ROE) -0.91

Liquidity (mrq)
Quick Ratio 4.98
Current Ratio 4.98

Balance Sheet (mrq) ($M)
Current Assets 75.81
Assets 79.90
Liabilities 18.23
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -76.24
Net Income -71.27

Cash Flow Statement (mra) ($M)
Cash From Operations -62.60
Cash from Investing -0.53
Cash from Financing 47.88

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-11 13G/A Soleus Capital Master Fund, L.P. 9.96 51.40
11-14 13G/A Avidity Partners Management LP 0.00 -100.00
11-14 13G/A Soleus Private Equity Fund III, L.P. 9.00
11-08 13G BlackRock, Inc. 5.30 0.00
11-04 13G/A Sphera Funds Management Ltd. 1.25
2024-02-14 13G/A Qiming U.S. Healthcare Fund II, L.P. 6.20
2024-02-09 13D/A Velan Capital Investment Management LP 9.80

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 44,232 187,668 23.57
2025-03-06 77,739 300,867 25.84
2025-03-05 93,958 306,336 30.67
2025-03-04 171,090 580,231 29.49

(click for more detail)

Similar Companies
IRD – Opus Genetics, Inc. ITRM – Iterum Therapeutics plc
JAGX – Jaguar Health, Inc. KALA – KALA BIO, Inc.
KPRX – Kiora Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io